Why AnaptysBio is on investors’ radar

AnaptysBio (ANAB) has attracted attention after a recent share price move, with the stock showing double digit returns over the past week, month and past 3 months. This performance is prompting some investors to reassess its profile.

Beyond the recent surge, the momentum in AnaptysBio’s share price return has been building for some time, and the very large 1 year total shareholder return suggests investors have been reassessing both its growth prospects and risk profile.

If biotech momentum has your attention, this could be a good moment to broaden your watchlist and check out 33 healthcare AI stocks

After such strong recent returns and a very large 1 year total shareholder return, the key question is whether AnaptysBio’s current price still reflects a discount to its potential or whether the market is already pricing in future growth.

Preferred Price-to-Sales of 8.2x: Is it justified?

On a P/S basis, AnaptysBio at a last close of $66.76 is priced below many peers, with its 8.2x ratio pointing to a potential discount versus similar biotech names.

The P/S multiple compares the company’s market value to its revenue and is often used for businesses that are not yet profitable, like AnaptysBio. For a clinical stage biotech with $234.6m in revenue and current losses, this metric helps investors focus on how the market values its sales pipeline and future monetisation potential rather than current earnings.

Compared with both the estimated fair P/S ratio of 4.5x and the wider US Biotechs industry average of 11x, AnaptysBio’s 8.2x sits in the middle. It is cheaper than many peers on sales, yet richer than the level that regression based fair value suggests the market could eventually move toward if expectations cool or execution disappoints.

Result: Price-to-sales of 8.2x (ABOUT RIGHT)

However, stronger expectations also raise the stakes. AnaptysBio’s current loss of $13.232m and its dependence on clinical and regulatory outcomes are key risks to watch.

Another view on value: DCF suggests a different story

While the 8.2x P/S ratio points to AnaptysBio being cheaper than many biotech peers, the SWS DCF model paints a very different picture. With an estimated future cash flow value of $334.81 per share versus a current price of $66.76, the model implies a very large potential undervaluation. That gap could reflect opportunity or simply very optimistic assumptions. Which side of the argument do you lean toward?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out AnaptysBio for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 50 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of strong recent returns, a higher P/S multiple and a bullish DCF view feels conflicting, that is exactly why it pays to look closer and move early while the data is fresh, then weigh up the 2 key rewards and 2 important warning signs.

Ready for more investment ideas?

Do not stop with a single stock when there are entire lists of ideas built from the same data driven approach, especially if you want options that match your style.

• Target potential bargains early by scanning companies that screen as 50 high quality undervalued stocks before attention crowds in elsewhere.
• Lock in income possibilities by reviewing businesses that appear in our 13 dividend fortresses and might suit a yield focused portfolio.
• Prioritise resilience by shortlisting companies in the 69 resilient stocks with low risk scores if capital preservation sits high on your list.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.